Pradaxa Clinical Trial Data
Clinical trials for Pradaxa (dabigatran etexilate mesylate) have explored its efficacy and safety in various patient populations, primarily focusing on its role as an anticoagulant. The pivotal RE-LY trial [1] compared Pradaxa to warfarin in patients with atrial fibrillation (AF).
What did the RE-LY trial show about Pradaxa?
The RE-LY trial demonstrated that Pradaxa at a 150 mg twice-daily dose was superior to warfarin in preventing stroke and systemic embolism [1]. It also showed comparable efficacy to warfarin at a 110 mg twice-daily dose for this outcome, with a significantly lower rate of major bleeding [1]. The trial enrolled over 18,000 patients and was a key study in the approval of Pradaxa [1].
How does Pradaxa's safety profile look in trials?
While Pradaxa showed a reduced risk of certain types of bleeding compared to warfarin in the RE-LY trial, it was associated with a higher rate of gastrointestinal bleeding [1]. Other clinical trials have also monitored adverse events. For instance, studies investigating its use in venous thromboembolism (VTE) treatment and extended prophylaxis have also reported on bleeding risks, which are a primary concern for anticoagulant medications [2][3].
What other conditions have Pradaxa's clinical trials addressed?
Beyond atrial fibrillation, Pradaxa has been studied for the prevention of stroke and systemic embolism in patients with non-valvular AF [1]. It has also been evaluated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as for the extended treatment of DVT and PE to reduce the risk of recurrence [2][3]. Studies have also looked at its use in patients undergoing hip or knee replacement surgery to prevent VTE [4].
Are there ongoing studies for Pradaxa?
Research continues to explore the optimal use of Pradaxa, including investigations into reversal agents and its role in specific patient subgroups. Post-marketing studies and real-world evidence continue to gather data on its long-term safety and effectiveness [5].
How do Pradaxa's trial results compare to other anticoagulants?
Comparative effectiveness research, often drawing from large-scale trials and real-world data, seeks to position Pradaxa against other anticoagulants like warfarin and newer direct oral anticoagulants (DOACs). These comparisons generally focus on efficacy in preventing thrombotic events and the incidence of different types of bleeding [5][6].
Sources:
[1] http://www.nejm.org/doi/full/10.1056/NEJMoa1005563
[2] http://www.nejm.org/doi/full/10.1056/NEJMoa1207889
[3] http://www.nejm.org/doi/full/10.1056/NEJMoa1302570
[4] http://www.nejm.org/doi/full/10.1056/NEJMoa1111778
[5] https://www.drugpatentwatch.com/
[6] https://www.ema.europa.eu/en/documents/assessment-report/pradaxa-epar-scientific-discussion_en.pdf